The groundbreaking treatment of the medication represents a exciting advance in the handling of diabetes mellitus type 2. Different to existing medications, tirzepatide affects multiple pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – leading to